Media

Bourne Partners' Portfolio Company enters into an Exclusive Licensing Agreement with Nephron Pharmaceuticals

Bourne Partners' Portfolio Company, BurnsAdler Pharmaceuticals, Inc. enters into an Exclusive Licensing Agreement with Nephron Pharmaceuticals to commercialize S2® Racepinephrine and Ipratropium Bromide and Albuterol Sulfate in Mexico

See full press release

Receive Your Report By Email